Modified posterior pelvic exenteration for advanced ovarian malignancies: a single-institution study of 35 cases

Minář, Luboš; Felsinger, Michal; Rovný, Ivo; Zlámal, Filip; Bienertová-Vašků, Julie; Jandáková, Eva

doi:10.1111/aogs.13177

Cited by 7 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although numerous reasons for delaying chemotherapy have been established [23][24][25], the influence of infection on treatment delays has not been evaluated in women with advanced-stage (III and IV) ovarian cancer following MPE.…”

Section: Introductionmentioning

confidence: 99%

An analysis of the influence of infection on overall survival rates, following modified posterior pelvic exenteration for advanced ovarian cancer

Szymankiewicz¹,

Dziobek²,

Sznajdorwska³

et al. 2018

Ginekol Pol

View full text Add to dashboard Cite

Objectives:The aim of our study was to determine the association between the appearance of infection after modified posterior pelvic exenteration (MPE) and the time to adjuvant chemotherapy (TTC), and to examine whether infection has any impact on clinical results by delaying the start of chemotherapy. Material and methods:Our retrospective study analyzed 77 patients who had undergone MPE followed by adjuvant chemotherapy. Postoperatively, either there was no residual tumor or, the residual tumor was less than 2.5 mm, in 76.7% of the study patients. Our study group was divided into two subgroups for comparison; the first group consisted of 41 patients with postoperative infections, and the second group of 36 patients had no infections. The infections of the first group were monitored during a 90-day postoperative period. Median TTC and overall survival rates (OS) were determined for those patients who developed an infection as well as for those who did not. Results:The expected 5-year survival rate was 0.40 (SD = 0.09) for those patients without infection and 0.17 (SD = 0.07) for those patients with infection. The survival curves of patients with infection and those without infection were significantly different statistically (p = 0.038). The median TTC differed significantly for those patients who developed infection compared with those patients who did not develop infection (37 days compared with 27.5 days respectively, p = 0.024); and patients without infection were statistically more likely to receive chemotherapy within 25 days following surgery than in the subsequent 25-42-day period compared with those patients who did develop infection (p = 0.048). No statistically significant differences were found between the two groups in relation to results following the initiation of chemotherapy during the first 42 days postoperatively (p = 0.445). Conclusions:The absence of postoperative infection was associated with better survival rates. Patients with infection experienced a longer time interval between surgery and the start of chemotherapy, without negative impact to their overall survival rates.

show abstract

Section: Introductionmentioning

confidence: 99%